|
JP4334866B2
(ja)
|
2000-10-09 |
2009-09-30 |
アイシス イノヴェイション リミテッド |
治療用抗体
|
|
US8293685B2
(en)
|
2007-07-26 |
2012-10-23 |
The Regents Of The University Of California |
Methods for enhancing bacterial cell display of proteins and peptides
|
|
CA2696263C
(en)
|
2007-08-15 |
2017-06-13 |
Bing Liu |
Monospecific and multispecific antibodies and method of use
|
|
EP2190861A4
(en)
*
|
2007-08-22 |
2011-03-30 |
Univ California |
ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
|
|
US8895702B2
(en)
*
|
2008-12-08 |
2014-11-25 |
City Of Hope |
Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
|
|
EP3543256A1
(en)
*
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
US8399219B2
(en)
*
|
2009-02-23 |
2013-03-19 |
Cytomx Therapeutics, Inc. |
Protease activatable interferon alpha proprotein
|
|
AU2010229705A1
(en)
*
|
2009-03-27 |
2011-10-20 |
Zymogenetics, Inc. |
Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
|
|
US9193791B2
(en)
|
2010-08-03 |
2015-11-24 |
City Of Hope |
Development of masked therapeutic antibodies to limit off-target effects
|
|
HRP20150664T1
(hr)
*
|
2010-12-03 |
2015-07-31 |
Adamed Sp. Z O.O. |
Antikancerogeni fuzijski protein
|
|
US8580922B2
(en)
|
2011-03-04 |
2013-11-12 |
Shire Human Genetic Therapies, Inc. |
Peptide linkers for polypeptide compositions and methods for using same
|
|
BR112013022557A2
(pt)
*
|
2011-03-04 |
2017-08-01 |
Shire Human Genetic Therapies |
ligantes de peptídeo composições de polipeptídeo e métodos para uso dos mesmos
|
|
WO2012123755A1
(en)
|
2011-03-17 |
2012-09-20 |
The University Of Birmingham |
Re-directed immunotherapy
|
|
PL394618A1
(pl)
*
|
2011-04-19 |
2012-10-22 |
Adamed Spólka Z Ograniczona Odpowiedzialnoscia |
Przeciwnowotworowe bialko fuzyjne
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
PE20150605A1
(es)
|
2012-04-27 |
2015-05-28 |
Cytomx Therapeutics Inc |
Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
|
|
US8822423B2
(en)
|
2012-05-17 |
2014-09-02 |
Janssen Biotech, Inc. |
Affinity peptides toward infliximab
|
|
WO2013192546A1
(en)
|
2012-06-22 |
2013-12-27 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and mehtods of using the same
|
|
SG11201408554QA
(en)
|
2012-06-22 |
2015-02-27 |
Cytomx Therapeutics Inc |
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
|
|
EP2882844B1
(en)
|
2012-08-10 |
2018-10-03 |
Cytomx Therapeutics Inc. |
Protease-resistant systems for polypeptide display and methods of making and using thereof
|
|
US9376489B2
(en)
|
2012-09-07 |
2016-06-28 |
Novartis Ag |
IL-18 binding molecules
|
|
US9487590B2
(en)
|
2012-09-25 |
2016-11-08 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
|
|
JP6605957B2
(ja)
|
2013-01-04 |
2019-11-13 |
シトムクス セラピューティクス,インコーポレイティド |
生体系におけるプロテアーゼ活性を検出するための組成物及び方法
|
|
EP2970498A4
(en)
*
|
2013-03-15 |
2016-11-23 |
Bayer Healthcare Llc |
PRODUCT ANTIBODIES DIRECTED AGAINST THE INHIBITOR OF THE PATHWAY OF TISSUE FACTOR
|
|
SG11201509595PA
(en)
*
|
2013-05-28 |
2015-12-30 |
Dcb Usa Llc |
Antibody locker for the inactivation of protein drug
|
|
BR112015030514A2
(pt)
|
2013-06-04 |
2017-08-29 |
Cytomx Therapeutics Inc |
Composições e métodos para conjugação de anticorpos ativáveis
|
|
WO2015000062A1
(en)
|
2013-07-05 |
2015-01-08 |
Avidbiologics Inc. |
Egfr antibody conjugates
|
|
JP6693872B2
(ja)
|
2013-07-25 |
2020-05-13 |
シトムクス セラピューティクス,インコーポレイティド |
多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
|
|
KR20250051130A
(ko)
*
|
2013-09-25 |
2025-04-16 |
싸이톰스 테라퓨틱스, 인크. |
매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
|
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
WO2015089283A1
(en)
|
2013-12-11 |
2015-06-18 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
HUE050159T2
(hu)
|
2013-12-17 |
2020-11-30 |
Genentech Inc |
Anti-CD3 antitestek és alkalmazási eljárások
|
|
EP3092256B1
(en)
|
2014-01-10 |
2022-05-18 |
Birdie Biopharmaceuticals Inc. |
Compounds and compositions for immunotherapy
|
|
EP3628328B1
(en)
|
2014-01-31 |
2022-09-14 |
Cytomx Therapeutics Inc. |
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
|
|
DK4001311T3
(da)
|
2014-07-09 |
2026-02-02 |
Birdie Biopharmaceuticals Inc |
Anti-pd-l1/pd-1-kombinationer til behandling af tumorer
|
|
CN112546230A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
JP6805142B2
(ja)
|
2014-11-21 |
2020-12-23 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Cd73に対する抗体およびその使用
|
|
AR103268A1
(es)
|
2014-12-23 |
2017-04-26 |
Bristol Myers Squibb Co |
Anticuerpos contra tigit
|
|
IL300408B2
(en)
|
2015-01-20 |
2025-11-01 |
Cytomx Therapeutics Inc |
Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
|
|
AU2016215604B2
(en)
|
2015-02-02 |
2020-08-13 |
The University Of Birmingham |
Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
|
|
MA42971A
(fr)
*
|
2015-03-13 |
2018-08-15 |
Cytomx Therapeutics Inc |
Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
|
|
EP3778640A1
(en)
|
2015-05-01 |
2021-02-17 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
|
AU2016258988A1
(en)
|
2015-05-04 |
2017-12-07 |
Cytomx Therapeutics, Inc |
Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
|
|
BR112017023872A2
(pt)
|
2015-05-04 |
2018-07-24 |
Cytomx Therapeutics Inc |
anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
|
|
TWI787796B
(zh)
|
2015-05-04 |
2022-12-21 |
美商Cytomx生物製藥公司 |
抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
|
|
JP6841754B2
(ja)
|
2015-05-13 |
2021-03-10 |
中外製薬株式会社 |
多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
|
|
EP3297672B1
(en)
|
2015-05-21 |
2021-09-01 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
AU2016271111B2
(en)
|
2015-05-29 |
2022-04-28 |
Bristol-Myers Squibb Company |
Antibodies against OX40 and uses thereof
|
|
DK3303394T3
(da)
|
2015-05-29 |
2020-07-06 |
Agenus Inc |
Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
|
|
US20180153884A1
(en)
|
2015-05-31 |
2018-06-07 |
Curegenix Corporation |
Combination compositions for immunotherapy
|
|
EP3310811B1
(en)
|
2015-06-16 |
2021-06-16 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
CN107709356A
(zh)
|
2015-06-26 |
2018-02-16 |
南加利福尼亚大学 |
用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
|
|
MX2017016502A
(es)
|
2015-06-29 |
2018-03-12 |
Univ Rockefeller |
Anticuerpos contra cd40 con actividad agonista mejorada.
|
|
MX383464B
(es)
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
US11466093B2
(en)
|
2015-07-27 |
2022-10-11 |
The General Hospital Corporation |
Antibody derivatives with conditionally enabled effector function
|
|
RU2740672C2
(ru)
|
2015-08-07 |
2021-01-19 |
ЭйЭлЭкс Онколоджи Инк. |
Конструкции, имеющие sirp-альфа домен или его вариант
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
JP6869987B2
(ja)
|
2015-09-01 |
2021-05-12 |
アジェナス インコーポレイテッド |
抗pd−1抗体及びその使用方法
|
|
WO2017075537A1
(en)
|
2015-10-30 |
2017-05-04 |
Aleta Biotherapeutics Inc. |
Compositions and methods for treatment of cancer
|
|
MA43134A
(fr)
|
2015-10-30 |
2018-09-05 |
Aleta Biotherapeutics Inc |
Compositions et méthodes de transduction tumorale
|
|
HUE054131T2
(hu)
|
2015-11-19 |
2021-08-30 |
Revitope Ltd |
Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
|
|
EP3389720A1
(en)
|
2015-12-18 |
2018-10-24 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
|
AU2017228470A1
(en)
|
2016-03-04 |
2018-08-30 |
Bristol-Myers Squibb Company |
Combination therapy with anti-CD73 antibodies
|
|
KR102530742B1
(ko)
|
2016-05-20 |
2023-05-09 |
하푼 테라퓨틱스, 인크. |
단일 도메인 혈청 알부민 결합 단백질
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
HRP20251020T1
(hr)
|
2016-05-20 |
2025-10-24 |
Harpoon Therapeutics, Inc. |
Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
|
|
TW201809013A
(zh)
|
2016-06-06 |
2018-03-16 |
艾斯克立必恩股份有限公司 |
用於藥物遞送之抗體融合蛋白
|
|
CN109715196A
(zh)
|
2016-06-13 |
2019-05-03 |
转矩医疗股份有限公司 |
用于促进免疫细胞功能的组合物和方法
|
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
CA3037767A1
(en)
|
2016-09-28 |
2018-04-05 |
Georgia Tech Research Corporation |
Methods and compositions for noninvasive detection of organ transplant rejection
|
|
CN110072890B
(zh)
*
|
2016-11-03 |
2022-11-29 |
百时美施贵宝公司 |
可活化的抗ctla-4抗体及其用途
|
|
EP3541843A1
(en)
|
2016-11-15 |
2019-09-25 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
KR102275008B1
(ko)
|
2016-11-23 |
2021-07-13 |
하푼 테라퓨틱스, 인크. |
전립선 특이 막 항원 결합 단백질
|
|
JP7215997B2
(ja)
|
2016-11-23 |
2023-01-31 |
ハープーン セラピューティクス,インク. |
前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法
|
|
CA3041279A1
(en)
|
2016-11-28 |
2018-05-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding domain, and polypeptide including conveying section
|
|
AU2017364818C1
(en)
|
2016-11-28 |
2025-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand binding activity
|
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
|
IL307242B1
(en)
|
2016-12-07 |
2026-07-01 |
Agenus Inc |
Anti-CTLA-4 antibodies and methods of using them
|
|
CN110300599B
(zh)
|
2016-12-07 |
2024-07-02 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
EP3551667A4
(en)
*
|
2016-12-09 |
2020-06-17 |
Seattle Genetics, Inc. |
BIVALENT ANTIBODIES MASKED BY COILS
|
|
EP3585817A4
(en)
*
|
2017-02-22 |
2020-12-02 |
Aleta Biotherapeutics Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
|
|
JP7556687B2
(ja)
|
2017-02-24 |
2024-09-26 |
中外製薬株式会社 |
薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法
|
|
WO2018160754A2
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
WO2018160671A1
(en)
*
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Targeted checkpoint inhibitors and methods of use
|
|
JP2020511130A
(ja)
|
2017-03-09 |
2020-04-16 |
サイトメックス セラピューティクス インコーポレイテッド |
Cd147抗体、活性化可能cd147抗体、ならびにその作製および使用の方法
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
MY200973A
(en)
|
2017-04-11 |
2024-01-26 |
Inhibrx Inc |
Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
|
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
|
US12460208B2
(en)
|
2017-04-18 |
2025-11-04 |
Parr Biotechnology Co., Ltd. |
Immunomodulatory polynucleotides and uses thereof
|
|
SG10202107880XA
(en)
|
2017-05-12 |
2021-09-29 |
Harpoon Therapeutics Inc |
Mesothelin binding proteins
|
|
US10730954B2
(en)
|
2017-05-12 |
2020-08-04 |
Harpoon Therapeutics, Inc. |
MSLN targeting trispecific proteins and methods of use
|
|
IL270743B2
(en)
|
2017-05-19 |
2024-09-01 |
Wuxi Biologics Shanghai Co Ltd |
Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof
|
|
CN109400711B
(zh)
*
|
2017-05-31 |
2022-02-08 |
四川大学华西医院 |
一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
|
|
CN110914302A
(zh)
|
2017-06-01 |
2020-03-24 |
赛托姆克斯治疗学股份有限公司 |
可活化抗pdl1抗体及其使用方法
|
|
JP2020528878A
(ja)
*
|
2017-06-20 |
2020-10-01 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
がん治療用インターフェロンプロドラッグ
|
|
US10716858B2
(en)
|
2017-06-30 |
2020-07-21 |
Massachusetts Institute Of Technology |
Branched multi-functional macromonomers and uses thereof
|
|
US11220544B2
(en)
|
2017-07-14 |
2022-01-11 |
Cytomx Therapeutics, Inc. |
Anti-CD166 antibodies and uses thereof
|
|
JP2020530554A
(ja)
|
2017-07-20 |
2020-10-22 |
シートムエックス セラピューティクス,インコーポレイテッド |
活性化抗体の特性を定性的および/または定量的に分析する方法およびその使用
|
|
WO2019036433A2
(en)
|
2017-08-16 |
2019-02-21 |
Bristol-Myers Squibb Company |
ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
CN111212853A
(zh)
|
2017-08-30 |
2020-05-29 |
西托姆克斯治疗公司 |
可活化的抗cd166抗体及其使用方法
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
CA3078969A1
(en)
|
2017-10-13 |
2019-04-18 |
Harpoon Therapeutics, Inc. |
Trispecific proteins and methods of use
|
|
CN111247171A
(zh)
|
2017-10-14 |
2020-06-05 |
西托姆克斯治疗公司 |
抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
|
|
PE20210125A1
(es)
|
2017-10-14 |
2021-01-19 |
Abbvie Inc |
Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos
|
|
US12564632B2
(en)
*
|
2017-11-08 |
2026-03-03 |
Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. |
Conjugates of biomolecule and use thereof
|
|
KR20250134208A
(ko)
|
2017-11-28 |
2025-09-09 |
추가이 세이야쿠 가부시키가이샤 |
항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
|
|
KR20200089312A
(ko)
|
2017-11-28 |
2020-07-24 |
추가이 세이야쿠 가부시키가이샤 |
리간드 결합 활성을 조정 가능한 리간드 결합 분자
|
|
AR113862A1
(es)
|
2017-12-01 |
2020-06-17 |
Seattle Genetics Inc |
Anticuerpos anti-cd47 y sus usos para tratar cáncer
|
|
CN111788227B
(zh)
|
2017-12-27 |
2025-02-25 |
百时美施贵宝公司 |
抗cd40抗体及其用途
|
|
WO2019148444A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
WO2019160007A1
(ja)
|
2018-02-14 |
2019-08-22 |
中外製薬株式会社 |
抗原結合分子および組合せ
|
|
CA3115461A1
(en)
*
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
WO2019173771A1
(en)
|
2018-03-09 |
2019-09-12 |
Cytomx Therapeutics, Inc. |
Activatable cd147 antibodies and methods of making and use thereof
|
|
CN112005304A
(zh)
|
2018-03-20 |
2020-11-27 |
西托姆克斯治疗公司 |
用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法
|
|
SG11202008593PA
(en)
|
2018-03-21 |
2020-10-29 |
Five Prime Therapeutics Inc |
ANTIBODIES BINDING TO VISTA AT ACIDIC pH
|
|
TW202010757A
(zh)
|
2018-04-11 |
2020-03-16 |
美商英伊布里克斯公司 |
具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
|
|
US20210324088A1
(en)
|
2018-05-02 |
2021-10-21 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
CA3099419A1
(en)
|
2018-05-04 |
2019-11-07 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
|
US20210130430A1
(en)
|
2018-05-14 |
2021-05-06 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
MX2020012251A
(es)
|
2018-05-14 |
2021-04-28 |
Werewolf Therapeutics Inc |
Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
|
|
MX2020012217A
(es)
*
|
2018-05-14 |
2021-03-02 |
Harpoon Therapeutics Inc |
Porción de unión para activación condicional de moléculas de inmunoglobulina.
|
|
WO2019222296A1
(en)
*
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
WO2019222278A1
(en)
*
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Dual binding moiety
|
|
EP3816182A4
(en)
|
2018-05-30 |
2022-07-13 |
Chugai Seiyaku Kabushiki Kaisha |
LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY
|
|
EP3807312A4
(en)
|
2018-05-30 |
2022-07-20 |
Chugai Seiyaku Kabushiki Kaisha |
POLYPEPTIDE WITH AGGRECAN-BINDING DOMAIN AND A CARRIER UNIT
|
|
MX2020014290A
(es)
|
2018-06-22 |
2021-08-05 |
Cugene Inc |
Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
|
|
AU2019301120A1
(en)
|
2018-07-11 |
2021-02-25 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
|
WO2020023553A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
WO2020023702A1
(en)
|
2018-07-25 |
2020-01-30 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
SG11202013248YA
(en)
*
|
2018-07-31 |
2021-02-25 |
Amgen Inc |
Pharmaceutical formulations of masked antibodies
|
|
US12435137B2
(en)
|
2018-08-03 |
2025-10-07 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing two antigen-binding domains that are linked to each other
|
|
US10988491B2
(en)
|
2018-08-17 |
2021-04-27 |
Massachusetts Institute Of Technology |
Degradable polymers of a cyclic silyl ether and uses thereof
|
|
EP3849611A4
(en)
*
|
2018-09-11 |
2022-06-15 |
Georgia Tech Research Corporation |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY PROFILING
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN119306844A
(zh)
|
2018-09-25 |
2025-01-14 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
JP2022501325A
(ja)
|
2018-09-28 |
2022-01-06 |
中外製薬株式会社 |
改変された抗体可変領域を含む抗原結合分子
|
|
AU2019356573B2
(en)
|
2018-10-11 |
2025-12-18 |
Inhibrx Biosciences, Inc. |
PD-1 single domain antibodies and therapeutic compositions thereof
|
|
JP7611820B2
(ja)
|
2018-10-11 |
2025-01-10 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Dll3シングルドメイン抗体およびその治療用組成物
|
|
CN113166261A
(zh)
|
2018-10-11 |
2021-07-23 |
印希比股份有限公司 |
B7h3单域抗体及其治疗性组合物
|
|
US12590169B2
(en)
|
2018-10-11 |
2026-03-31 |
Inhibrx Biosciences, Inc. |
5T4 single domain antibodies and therapeutic compositions thereof
|
|
TWI897855B
(zh)
|
2018-10-26 |
2025-09-21 |
美商免疫遺傳股份有限公司 |
E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
|
|
BR112021008526A2
(pt)
|
2018-11-02 |
2021-08-10 |
Cytomx Therapeutics, Inc. |
anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
|
|
MX2021005708A
(es)
|
2018-11-16 |
2021-09-21 |
Bristol Myers Squibb Co |
Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
|
|
JP2022512124A
(ja)
|
2018-12-06 |
2022-02-02 |
シートムエックス セラピューティクス,インコーポレイテッド |
マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
|
|
BR112021012631A2
(pt)
|
2018-12-26 |
2021-12-14 |
Xilio Dev Inc |
Anticorpos anti-ctla4 e métodos de uso dos mesmos
|
|
WO2020176672A1
(en)
|
2019-02-26 |
2020-09-03 |
Cytomx Therapeutics, Inc. |
Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
|
|
US20220154174A1
(en)
*
|
2019-03-08 |
2022-05-19 |
Oxford Genetics Limited |
Method of Selecting for Antibodies
|
|
MA55316A
(fr)
|
2019-03-13 |
2022-01-19 |
Merck Sharp & Dohme |
Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1
|
|
AU2020240310A1
(en)
|
2019-03-21 |
2021-10-07 |
Immunogen, Inc. |
Methods of preparing cell-binding agent-drug conjugates
|
|
US11851487B2
(en)
*
|
2019-04-01 |
2023-12-26 |
Rensselaer Polytechnic Institute |
Methods and systems for detecting peptide aggregates
|
|
US12582726B1
(en)
|
2019-04-05 |
2026-03-24 |
Earli Inc. |
Synthetic cancer-specific promoters
|
|
EP3946470A4
(en)
*
|
2019-04-05 |
2023-05-31 |
Earli Inc. |
IMPROVED METHODS AND COMPOSITIONS FOR SYNTHETIC BIOMARKERS
|
|
JP7720785B2
(ja)
|
2019-04-18 |
2025-08-08 |
ブリストル-マイヤーズ スクイブ カンパニー |
低pHで結合するために特異性が増強されたイピリムマブバリアント
|
|
RS64961B1
(sr)
|
2019-04-26 |
2024-01-31 |
Immunogen Inc |
Derivati kamptotecina
|
|
WO2020232303A1
(en)
|
2019-05-14 |
2020-11-19 |
Harpoon Therapeutics, Inc. |
EpCAM BINDING PROTEINS AND METHODS OF USE
|
|
BR112021022666A2
(pt)
|
2019-05-14 |
2022-03-29 |
Werewolf Therapeutics Inc |
Frações de separação e seus métodos e uso
|
|
EP3972982A1
(en)
|
2019-05-20 |
2022-03-30 |
Massachusetts Institute of Technology |
Boronic ester prodrugs and uses thereof
|
|
CA3141130A1
(en)
|
2019-05-31 |
2020-12-03 |
ALX Oncology Inc. |
Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
|
|
CN113905757B
(zh)
|
2019-06-05 |
2026-01-13 |
中外制药株式会社 |
抗体切割位点结合分子
|
|
EP3981428A4
(en)
|
2019-06-05 |
2023-07-12 |
Chugai Seiyaku Kabushiki Kaisha |
Protease substrate, and polypeptide including protease cleavage sequence
|
|
TW202112354A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
遮蔽抗體調配物
|
|
TW202112801A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
純化遮蔽抗體之方法
|
|
US20220251206A1
(en)
|
2019-06-11 |
2022-08-11 |
Bristol-Myers Squibb Company |
Anti-ctla4 antibody prodruggable (probody) at a cdr position
|
|
CN114341189A
(zh)
|
2019-06-12 |
2022-04-12 |
奥美药业有限公司 |
全新il-15前药及其应用
|
|
US20220306745A1
(en)
|
2019-06-13 |
2022-09-29 |
Cytomx Therapeutics, Inc. |
Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer
|
|
WO2020252358A1
(en)
|
2019-06-13 |
2020-12-17 |
Cytomx Therapeutics, Inc. |
Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancer
|
|
WO2020256546A1
(en)
|
2019-06-17 |
2020-12-24 |
Tagworks Pharmaceuticals B.V. |
Compounds for fast and efficient click release
|
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
|
EP4017594A1
(en)
*
|
2019-08-21 |
2022-06-29 |
Askgene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
CN112480263B
(zh)
*
|
2019-09-12 |
2026-06-05 |
百欧恩泰(苏州)医药有限公司 |
一种双特异t细胞激活器活化t细胞的设计及其应用
|
|
CA3149719A1
(en)
|
2019-09-19 |
2021-03-25 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
|
EP4034171A1
(en)
|
2019-09-23 |
2022-08-03 |
Cytomx Therapeutics Inc. |
Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
|
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
|
WO2021108693A1
(en)
|
2019-11-27 |
2021-06-03 |
ALX Oncology Inc. |
Combination therapies for treating cancer
|
|
WO2021141662A1
(en)
|
2020-01-10 |
2021-07-15 |
Massachusetts Institute Of Technology |
Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof
|
|
AU2021205981A1
(en)
|
2020-01-11 |
2022-07-14 |
AskGene Pharma, Inc. |
Novel masked cytokines and methods of use thereof
|
|
US12662535B2
(en)
|
2020-01-17 |
2026-06-23 |
Immunelogic Therapeutics, Inc. |
Pro-antibody that reduces off-target toxicity
|
|
CN115943210A
(zh)
|
2020-01-20 |
2023-04-07 |
中外制药株式会社 |
配体结合融合蛋白
|
|
EP4097129A1
(en)
|
2020-01-29 |
2022-12-07 |
Inhibrx, Inc. |
Cd28 single domain antibodies and multivalent and multispecific constructs thereof
|
|
JP7803856B2
(ja)
|
2020-02-05 |
2026-01-21 |
中外製薬株式会社 |
組換え抗原結合分子を製造するおよび/または濃縮するための方法
|
|
BR112022016550A2
(pt)
|
2020-02-21 |
2022-11-16 |
Harpoon Therapeutics Inc |
Proteínas de ligação a flt3 e métodos de uso
|
|
US20230140384A1
(en)
|
2020-03-09 |
2023-05-04 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
|
CA3173587A1
(en)
|
2020-03-31 |
2021-10-07 |
Chugai Seiyaku Kabushiki-Kaisha |
Dll3-targeting multispecific antigen-binding molecules and uses thereof
|
|
WO2021207657A1
(en)
|
2020-04-09 |
2021-10-14 |
Cytomx Therapeutics, Inc. |
Compositions containing activatable antibodies
|
|
AU2021254283B2
(en)
|
2020-04-10 |
2025-12-11 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
TW202229343A
(zh)
|
2020-08-21 |
2022-08-01 |
美商健臻公司 |
Fgfr3抗體及使用方法
|
|
EP4240493A2
(en)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
WO2022098638A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
JP7716473B2
(ja)
|
2020-11-04 |
2025-07-31 |
ジェネンテック, インコーポレイテッド |
抗cd20/抗cd3二重特異性抗体の皮下投薬
|
|
US20220153869A1
(en)
*
|
2020-11-16 |
2022-05-19 |
Tavotek Biotherapeutics (Hong Kong) Limited |
Shielded and homing bispecific antibody that simultaneously inhibits angiogenic pathway targets and her2 family proteins and uses thereof
|
|
JP2023550148A
(ja)
|
2020-11-20 |
2023-11-30 |
シンシア・イノベーション・インコーポレイテッド |
がん免疫治療に用いられる武装二重car-t組成物及び方法
|
|
CA3206549A1
(en)
|
2021-01-29 |
2022-08-04 |
Frederick G. Vogt |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
WO2022170619A1
(en)
*
|
2021-02-11 |
2022-08-18 |
Adagene Pte. Ltd. |
Anti-cd3 antibodies and methods of use thereof
|
|
EP4305063A1
(en)
*
|
2021-03-09 |
2024-01-17 |
Molecular Partners AG |
Protease cleavable prodrugs
|
|
KR20230157448A
(ko)
|
2021-03-16 |
2023-11-16 |
싸이톰스 테라퓨틱스, 인크. |
마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
JP2024520902A
(ja)
|
2021-05-13 |
2024-05-27 |
エーエルエックス オンコロジー インコーポレイテッド |
がんを治療するための併用療法
|
|
KR20240007171A
(ko)
|
2021-05-14 |
2024-01-16 |
제넨테크, 인크. |
모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
|
|
US12686715B2
(en)
|
2021-06-01 |
2026-07-21 |
Genentech, Inc. |
Methods for treatment of B cell proliferative disorders with anti-CD20/anti-CD3 bispecific antibodies
|
|
US20240352080A1
(en)
|
2021-07-14 |
2024-10-24 |
Seagen Inc. |
Antibody Masking Domains
|
|
KR20240035556A
(ko)
|
2021-07-19 |
2024-03-15 |
추가이 세이야쿠 가부시키가이샤 |
융합 폴리펩타이드를 이용하는 프로테아제 매개성의 표적 특이적 사이토카인 송달
|
|
WO2023049825A1
(en)
|
2021-09-24 |
2023-03-30 |
Seagen Inc. |
Improved antibody masking domains
|
|
JP2024538042A
(ja)
|
2021-10-13 |
2024-10-18 |
シートムエックス セラピューティクス,インコーポレイテッド |
三量体活性化可能サイトカイン構成体ならびに関連する組成物及び方法
|
|
US20250000892A1
(en)
*
|
2021-10-14 |
2025-01-02 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Programmable delivery platforms for rna structures
|
|
WO2023064955A1
(en)
|
2021-10-15 |
2023-04-20 |
Cytomx Therapeutics, Inc. |
Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
|
|
PE20241343A1
(es)
|
2021-10-15 |
2024-07-03 |
Cytomx Therapeutics Inc |
Complejo polipeptidico activable
|
|
US20230174995A1
(en)
|
2021-10-15 |
2023-06-08 |
Cytomx Therapeutics, Inc. |
Activatable polypeptide complex
|
|
WO2023100829A1
(ja)
*
|
2021-11-30 |
2023-06-08 |
第一三共株式会社 |
プロテアーゼ分解性マスク抗体
|
|
EP4469065A1
(en)
|
2022-01-28 |
2024-12-04 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
AU2023218678A1
(en)
|
2022-02-09 |
2024-08-01 |
Daiichi Sankyo Company, Limited |
Environmentally responsive masked antibody and use thereof
|
|
JP2025512798A
(ja)
|
2022-03-25 |
2025-04-22 |
サイトムエックス セラピューティクス,インク. |
活性化可能な二重アンカー型マスク化分子及びその使用方法
|
|
WO2023192973A1
(en)
|
2022-04-01 |
2023-10-05 |
Cytomx Therapeutics, Inc. |
Activatable multispecific molecules and methods of use thereof
|
|
EP4504782A2
(en)
|
2022-04-01 |
2025-02-12 |
CytomX Therapeutics, Inc. |
Cd3-binding proteins and methods of use thereof
|
|
WO2023222580A1
(en)
|
2022-05-16 |
2023-11-23 |
Byondis B.V. |
Novel masked antibodies
|
|
CN119630428A
(zh)
|
2022-07-12 |
2025-03-14 |
西托姆克斯治疗公司 |
Epcam免疫缀合物及其用途
|
|
US20260015425A1
(en)
|
2022-08-01 |
2026-01-15 |
Cytomx Therapeutics, Inc. |
Protease-cleavable substrates and methods of use thereof
|
|
TW202424184A
(zh)
|
2022-08-01 |
2024-06-16 |
美商Cytomx生物製藥公司 |
蛋白酶可切割部分及其使用方法
|
|
AR130077A1
(es)
|
2022-08-01 |
2024-10-30 |
Cytomx Therapeutics Inc |
Substratos escindibles por proteasas, y métodos de uso de los mismos
|
|
JP2025525868A
(ja)
|
2022-08-01 |
2025-08-07 |
サイトムエックス セラピューティクス,インク. |
プロテアーゼ切断性部分及びその使用方法
|
|
WO2024030845A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
|
WO2024039973A2
(en)
*
|
2022-08-05 |
2024-02-22 |
Staidson Biopharma Inc. |
Masking polypeptide, activatable novel prodrugs and methods of use thereof
|
|
WO2024150172A1
(en)
*
|
2023-01-11 |
2024-07-18 |
Bright Peak Therapeutics Ag |
Cleavable peptides and methods of use thereof
|
|
WO2024150175A1
(en)
*
|
2023-01-11 |
2024-07-18 |
Bright Peak Therapeutics Ag |
Conditionally activated proteins and methods of use
|
|
WO2024216170A2
(en)
|
2023-04-12 |
2024-10-17 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
EP4694934A1
(en)
|
2023-04-12 |
2026-02-18 |
CytomX Therapeutics, Inc. |
Masking polypeptides, activatable cytokine constructs, and related compositions and methods
|
|
WO2024212151A1
(en)
*
|
2023-04-13 |
2024-10-17 |
Adagene Pte. Ltd. |
Masked antibodies, libraries and methods of use
|
|
IL325907A
(en)
|
2023-07-13 |
2026-03-01 |
Iovance Biotherapeutics Inc |
Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
|
|
KR20260056204A
(ko)
|
2023-08-14 |
2026-04-24 |
보로 테라퓨틱스, 인코포레이티드 |
표적 세포에 대한 골수 세포 활성을 조건부로 촉진시키는 치료용 결합제 및 이의 용도
|
|
CN117534732B
(zh)
*
|
2023-11-03 |
2024-10-22 |
湖南中晟全肽生物科技股份有限公司 |
一种抑制il-12与其受体结合的多肽及其应用
|
|
CN122349537A
(zh)
|
2023-12-01 |
2026-07-07 |
阿布林克斯有限公司 |
识别人血清白蛋白、tcr和肿瘤抗原识别部分的多特异性抗体
|
|
WO2025235515A1
(en)
|
2024-05-07 |
2025-11-13 |
Cytomx Therapeutics, Inc. |
Activatable polypeptide complex formulations
|
|
WO2025240659A2
(en)
|
2024-05-14 |
2025-11-20 |
Cytomx Therapeutics, Inc. |
Activatable constructs, compositions and methods
|
|
WO2026006784A1
(en)
|
2024-06-28 |
2026-01-02 |
Iovance Biotherapeutics, Inc. |
Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
|
|
WO2026020161A1
(en)
|
2024-07-19 |
2026-01-22 |
Cytomx Therapeutics, Inc. |
Activatable il-12 constructs and related compositions and methods
|
|
WO2026024841A1
(en)
|
2024-07-24 |
2026-01-29 |
Astellas Us Llc |
Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
|
|
WO2026035650A2
(en)
|
2024-08-05 |
2026-02-12 |
Cytomx Therapeutics, Inc. |
Cleavable polypeptides and methods of use thereof
|
|
WO2026161794A1
(en)
|
2025-01-27 |
2026-07-30 |
Cytomx Therapeutics, Inc. |
Epcam immunoconjugates and therapeutic uses thereof
|